#1 Clinical Trials Search in Europe

Glepaglutide

Glepaglutide, also known as ZP1848, is an investigational drug being studied as a potential treatment for Short Bowel Syndrome (SBS). This article summarizes key information from clinical trials evaluating the safety, efficacy, and pharmacokinetics of glepaglutide in patients with SBS and healthy volunteers.

Table of Contents

What is Glepaglutide?

Glepaglutide, also known by its research name ZP1848, is a new medication being developed to treat Short Bowel Syndrome (SBS)[1]. It belongs to a class of drugs called Glucagon-Like Peptide-2 (GLP-2) analogs[5]. These drugs work by helping the intestines absorb more nutrients and fluids, which is especially important for people with SBS who have difficulty getting enough nutrition from food alone.

What Conditions Does It Treat?

Glepaglutide is specifically designed to treat Short Bowel Syndrome (SBS)[1]. SBS is a condition where a large portion of the small intestine is missing or doesn’t work properly. This can happen due to surgery, injury, or certain diseases. People with SBS often have trouble absorbing enough nutrients and fluids from their food, which can lead to malnutrition, dehydration, and other health problems.

How is It Administered?

Glepaglutide is given as an injection under the skin (subcutaneous injection). In clinical trials, it has been tested in different dosing schedules:

  • Once-weekly injections[1]
  • Twice-weekly injections[5]

The medication is delivered using a special device called an autoinjector, which makes it easier for patients to give themselves the injection at home[1].

Efficacy and Benefits

Clinical trials have shown several potential benefits of glepaglutide for patients with SBS:

  • Reduced need for parenteral support: Glepaglutide may help reduce the amount of intravenous nutrition (called parenteral support or PS) that SBS patients need. Some patients were able to reduce their PS volume by 20% or more[5].
  • Improved nutrient absorption: The drug appears to help the intestines absorb more fluids, energy, and nutrients like carbohydrates, lipids, and proteins[2].
  • Potential for improved quality of life: By reducing the need for PS and improving nutrient absorption, glepaglutide may help improve patients’ overall quality of life[5].

Safety and Side Effects

As with any medication, glepaglutide can cause side effects. Clinical trials are carefully monitoring for:

  • Adverse events (AEs): These are any undesirable experiences associated with the use of the drug[1].
  • Changes in vital signs: Researchers are monitoring things like blood pressure, heart rate, and body temperature[5].
  • Changes in ECG: This is a test that checks the electrical activity of the heart[5].
  • Immune system reactions: The body might develop antibodies against the drug, which could affect its effectiveness[5].

The full safety profile of glepaglutide is still being established through ongoing clinical trials.

Ongoing Research

Glepaglutide is still being studied in clinical trials. These trials are looking at:

  • Long-term safety and efficacy: Some trials are following patients for up to 2 years to see how well the drug works over time and to monitor for any long-term side effects[1].
  • Different patient groups: Researchers are studying how the drug works in people with different levels of kidney function[4].
  • Comparison to placebo: Some trials are comparing glepaglutide to a placebo (a substance with no active drug) to prove its effectiveness[5].

These ongoing studies will help determine if glepaglutide is safe and effective enough to be approved for widespread use in patients with Short Bowel Syndrome.

Aspect Details
Drug Name Glepaglutide (ZP1848)
Drug Class Glucagon-Like Peptide-2 (GLP-2) analog
Target Condition Short Bowel Syndrome (SBS)
Administration Subcutaneous injection (once or twice weekly)
Primary Outcome Reduction in parenteral support (PS) volume
Key Secondary Outcomes Nutrient absorption, quality of life, days off PS
Safety Assessments Adverse events, antibody formation, vital signs
Trial Durations 24-104 weeks

FAQ

  • What is glepaglutide? Glepaglutide is an investigational drug that is a Glucagon-Like Peptide-2 (GLP-2) analog. It is being studied as a potential treatment for Short Bowel Syndrome (SBS).
  • How is glepaglutide administered? In clinical trials, glepaglutide is typically administered as a subcutaneous (under the skin) injection. It has been studied with both once-weekly and twice-weekly dosing schedules.
  • What is the main goal of glepaglutide treatment in SBS patients? The primary goal of glepaglutide treatment in SBS patients is to reduce the volume of parenteral support (PS) needed. PS is intravenous nutrition and fluids required by many SBS patients.
  • What are some of the key outcomes being measured in glepaglutide clinical trials? Key outcomes include changes in weekly PS volume, absorption of nutrients and fluids, quality of life measures, and safety assessments such as adverse events and antibody formation.
  • How long do the clinical trials for glepaglutide typically last? The duration of glepaglutide clinical trials varies, but many of the phase 3 trials last 24-52 weeks, with some extension studies lasting up to 2 years to assess long-term safety and efficacy.

Ongoing Clinical Trials on Glepaglutide

  • Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • A Study to Evaluate the Long-Term Safety of Glepaglutide in Adult Patients with Short Bowel Syndrome Who Participated in Previous Studies

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Poland

  • Study on the Long-Term Safety of Glepaglutide for Adults with Short Bowel Syndrome

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany The Netherlands Poland

  • Study on the Long-Term Safety and Effectiveness of Glepaglutide for Patients with Short Bowel Syndrome

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany The Netherlands Poland

Glossary

  • Short Bowel Syndrome (SBS): A condition where a large portion of the small intestine is missing or has been surgically removed, leading to poor absorption of nutrients and fluids.
  • Parenteral Support (PS): Intravenous nutrition and fluids provided to patients who cannot absorb enough nutrients through their digestive system, often required by SBS patients.
  • Glucagon-Like Peptide-2 (GLP-2): A hormone that helps regulate the growth and function of intestinal cells. Glepaglutide is an analog (similar version) of this hormone.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Subcutaneous (SC) injection: An injection given into the fatty tissue just beneath the skin.
  • Autoinjector: A device used to deliver a pre-measured dose of medication through a spring-loaded syringe, making self-injection easier for patients.
  • Anti-drug Antibodies (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially affect the drug's efficacy or safety.
  • Metabolic Balance Study: A detailed assessment of nutrient intake and output to measure absorption and utilization of various nutrients in the body.

References